Share Price:

APNASPENAspen Pharmacare Hldgs9501-253 (-2.59%)

Aspen highlights the rising diabetes disease burden

Aspen marked World Diabetes Day by highlighting the alarming economic, social, productivity and reduced life expectancy impact that diabetes is having on South Africa

Aspen announces local availability of Lilly’s Mounjaro

Stephen Saad, Aspen Group Chief Executive

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.

Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day

Heinz Schütte, Aspen Pharmacare Regional CEO, Dr Reyna Daya, SEMDSA President & Endocrinologist, and Stavros Nicolau, Aspen Group Senior Executive Strategic Trade

Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.